Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 2290 • 2014 ACR/ARHP Annual Meeting
Race and Other Risk Markers of Uveitis in a Prospective Cohort of Children with Juvenile Idiopathic Arthritis
Sheila T. Angeles-Han¹, Courtney McCracken¹, Steven Yeh², Kirsten Jenkins³, Erica Myoung⁴, Daneka Stryker⁴, Kelly A. Rouster-Stevens⁵, Larry B. Vogler¹, Christine Kennedy⁶, Sampath Prahalad¹ and Carolyn Drews-Botsch⁷, ¹Emory University School of Medicine, Atlanta, GA, ²Ophthalmology, Emory University School of Medicine, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory University, Atlanta, GA, ⁵Pediatrics, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology Immunology, Emory Children's Center, Atlanta, GA, ⁷Epidemiology, Emory University School of Public Health, Atlanta, GA
Background/Purpose Juvenile idiopathic arthritis-associated uveitis (JIA-U) can lead to poor visual outcomes. American Academy of Pediatric guidelines recommend screening every 3 months in children with…
Abstract Number: 271 • 2014 ACR/ARHP Annual Meeting
Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN)
Lianne Kearsley-Fleet¹, Rebecca Davies¹, Mark Lunt¹, Taunton R. Southwood², Kimme L. Hyrich³ and on Behalf Of The BSPAR Etanercept Cohort Study¹, ¹Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, ²Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom
Background/Purpose: Etanercept (ETN) is licensed in Europe for use in children with Juvenile Idiopathic Arthritis (JIA) and is routinely prescribed after failure of other DMARDs.…
Abstract Number: 1866 • 2014 ACR/ARHP Annual Meeting
Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis
Debbie Ehrmann Feldman¹, Evelyne Vinet², Sasha Bernatsky³, Ciaran Duffy⁴, Elizabeth Hazel⁵, Marie-Pierre Sylvestre⁶, Garbis Meshefedjian⁷ and Anick Bérard¹, ¹Université de Montréal, Montréal, QC, Canada, ²McGill University Health Center, Montreal, QC, Canada, ³Clinical Epidemiology - Rheumatology, McGill University, Montreal, QC, Canada, ⁴Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁵McGill University Heatlh Center, Montreal, QC, Canada, ⁶médecine sociale et préventive, Université de Montréal, Montréal, QC, Canada, ⁷Public Health Department of Montreal, Montreal, QC, Canada
Background/Purpose: Although there is a higher frequency of adverse birth outcomes in women with rheumatoid arthritis, little is known on the subject regarding women who…
Abstract Number: 276 • 2014 ACR/ARHP Annual Meeting
Growth during Tocilizumab Therapy for Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial
Kamal N. Bharucha¹, Hermine I. Brunner², Nicola Ruperto³, David A. Cabral², Abraham Gedalia², Valeria Gerloni³, Christian Jorgensen³, Athimalaipet Ramanan³, Daniel Lovell², Alberto Martini⁴, James Frane⁵, Chris Wells⁶ and Fabrizio De Benedetti Sr.⁷, ¹Genentech, South San Francisco, CA, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Consultant, Santa Monica, CA, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy
Background/Purpose: Elevated interleukin-6 (IL-6) levels have been associated with low growth velocity in patients with juvenile idiopathic arthritis (JIA).1 The efficacy of tocilizumab (TCZ), an…
Abstract Number: 1444 • 2014 ACR/ARHP Annual Meeting
The Vocational Experiences of Young People with Juvenile Idiopathic Arthritis and the Role of the Multidisciplinary Team Supporting Positive Employment Outcomes
Helen Hanson¹, Ruth Hart², Alison Jordan³, Rachel Tattersall⁴, Ben Thompson¹ and Helen E. Foster⁵, ¹Rheumatology, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ²Institute of Health and Society, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ⁴Rheumatology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, ⁵Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Recent decades have seen marked changes in the management of juvenile idiopathic arthritis (JIA), with improved clinical outcomes for many patients. However, unemployment rates…
Abstract Number: 198 • 2014 ACR/ARHP Annual Meeting
Implant Survival and Patient-Reported Outcomes after Total Hip Arthroplasty in Young Patients with JIA
Ishaan Swarup¹, Ella Christoph¹, Lisa A. Mandl², Susan M. Goodman² and Mark P. Figgie³, ¹Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY
Background/Purpose : Juvenile Idiopathic Arthritis (JIA) is a common rheumatologic disease in children that often persists into adulthood. The hip joint is commonly involved, and…
Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting
Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Marc D. Natter¹, Mei-Sing Ong², Kenneth D. Mandl³, Laura Schanberg⁴, Yukiko Kimura⁵, Norman Ilowite⁶ and the CARRA Registry Investigators, ¹Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ²Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ³Intelligent Health Lab, Children's Hospital Boston, Boston, MA, ⁴Duke University, Durham, NC, ⁵Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁶Rheumatology, Children's Hospital Montefiore, Bronx, NY
Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…
Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting
A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study
Petra C.E. Hissink Muller^1,2, D.M.C. Brinkman^1,3, Dieneke Schonenberg⁴, Yvonne Koopman-Keemink⁵, J. Merlijn Van den Berg⁶, W.P. Bekkering⁷, Marion van Rossum^8,9, Lisette WA van Suijlekom-Smit¹⁰, Cornelia F. Allaart¹¹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade, Amsterdam, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatrics, Haga ziekenhuis, The Hague, Netherlands, ⁶Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁷Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, ⁸Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁹Reade, Amsterdam, Netherlands, ¹⁰Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, ¹¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
Abstract Number: 928 • 2014 ACR/ARHP Annual Meeting
A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Alessandro Consolaro¹, Amita Aggarwal², Troels Herlin³, Olga Vougiouka⁴, Rubén Burgos-Vargas⁵, Ilonka Orban⁶, Nahid Shafaie⁷, Maria Trachana⁸, Lidia Rutkowska-Sak⁹, Ingrida Rumba-Rozenfelde¹⁰, Dimitrina Mihaylova¹¹, Alberto Martini^12,13 and Angelo Ravelli^1,14, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, ⁵Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁷Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran, ⁸Aristotle University, Thessaloniki, Greece, ⁹Institute of Rheumatology, Warsaw, Poland, ¹⁰University of Latvia, Riga, Latvia, ¹¹University Children Hospital, Sofia, Bulgaria, ¹²Istituto Giannina Gaslini, Genova, Italy, ¹³University of Genova, Genova, Italy, ¹⁴Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose The epidemiology of juvenile idiopathic arthritis (JIA) is known to be variable worldwide and the therapeutic approach to JIA is not standardized. Moreover, the…
Abstract Number: 303 • 2014 ACR/ARHP Annual Meeting
Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study
Amir Rashid¹, Kate Holliday¹, Lis Cordingley¹, Roberto Carrasco¹, Bo Fu², Helen E. Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Lucy Wedderburn⁷, Kimme Hyrich⁸ and Wendy Thomson⁹, ¹Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ²Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁸Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
· Background/Purpose: Pain is the most common symptom of JIA and has been associated with disease activity. However, disease activity has only accounted for a…
Abstract Number: 298 • 2013 ACR/ARHP Annual Meeting
Preliminary Prospective Study Of Ultrasonography In Patients With Juvenile Idiopathic Arthritis In Clinical Remission: Subclinical Synovitis May Predict Flare?
Vanessa B Miotto e Silva¹, Sônia A.V. Mitraud², Rita NV Furtado³, Jamil Natour³ and Maria Teresa Terreri¹, ¹Pediatrics, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil, ²Radiology and Diagnostic Imaging, Escola Paulista de Medicina/ Universidade Federal de São Paulo (EPM/UNIFESP), São Paulo, Brazil, ³Internal Medicine, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood and has variable prognosis, characterized by periods of activity and remission.…
Abstract Number: 2792 • 2013 ACR/ARHP Annual Meeting
Pediatric Rheumatology Care and Outcomes Improvement Network Demonstrates Performance Improvement On Juvenile Idiopathic Arthritis Quality Measures
Julia G. Harris^1,2, Esi Morgan DeWitt³, Ronald M. Laxer^4,5, Stacy P. Ardoin⁶, Beth S. Gottlieb⁷, Judyann C. Olson^1,2, Murray H. Passo⁸, Jennifer E. Weiss⁹, Daniel J. Lovell¹⁰, Tzielan C. Lee¹¹, Sheetal S. Vora^12,13, Nancy Griffin¹⁴, Jason A. Stock¹⁵, Lynn M. Darbie¹⁴ and Catherine A. Bingham¹⁶, ¹Medical College of Wisconsin, Milwaukee, WI, ²Children's Hospital of Wisconsin, Milwaukee, WI, ³Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH, ⁷Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ⁸Pediatrics, Medical University of South Carolina, Charleston, SC, ⁹Pediatric Rheumatology, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ¹²University of North Carolina Chapel Hill, Chapel Hill, NC, ¹³Levine Children's Hospital and Carolinas Medical Center, Charlotte, NC, ¹⁴James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁵Biostatistics & Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁶Pediatric Rheumatology, Penn State Hershey Children's Hospital, Hershey, PA
Background/Purpose: Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a multi-site learning network designed to improve outcomes of juvenile idiopathic arthritis (JIA) care. Teams…
Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti¹, Hermine Brunner², Eileen M. Baildam³, Ruben Burgos-Vargas³, Gerd Horneff³, Hans-Iko Huppertz³, Kirsten Minden⁴, Barry L. Myones², Karen Onel⁵, Jianmei Wang⁶, Kamal N. Bharucha⁷, Daniel J. Lovell², Alberto Martini⁸ and Nicolino Ruperto³, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
Abstract Number: 2677 • 2013 ACR/ARHP Annual Meeting
Disease Progression Into Adulthood In Patients With Juvenile Idiopathic Arthritis – a Longitudinal 30 Year Follow-Up Study
Anne Marit Selvaag, Hanne Aulie, Vibke Lilleby and Berit Flatø, Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: The aim of the study was to assess disease activity and health status in a previously studied cohort of patients with juvenile idiopathic arthritis…
Abstract Number: 274 • 2013 ACR/ARHP Annual Meeting
Reported Macrophage Activation Syndrome In Patients With Systemic-Onset Juvenile Idiopathic Arthritis Treated With Tocilizumab
Shumpei Yokota^1,2, Yasuhiko Itoh^2,3, Tomohiro Morio^2,4, Naokata Sumitomo^2,5 and Seiji Minota^2,6, ¹Department of Pediatrics, Yokohama City University School of Medicine, Yokohama, Japan, ²The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan, ³pediatrics, Nippon Medical School, Tokyo, Japan, ⁴Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan, ⁵pediatrics, Nihon University School of Medicine, tokyo, Japan, ⁶Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke,Tochigi, Japan
Background/Purpose: Systemic-onset juvenile idiopathic arthritis (s-JIA) is a subtype of chronic childhood arthritis that is characterized by a spiking fever, rash, and arthritis. About 7%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].